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Recently Kl keratin peptide (Kl, 68 kDa) was found to be present in two kinds of cultured human squamous cell carcinomas (f_fSCs) using a low-salt 
aqueous solution, rather than the high-salt solution containing Triton X-100 employed by many researchers up until now. To confirm whether 
this phenomenon is universal in cultured HSCs we analyzed Kl peptide in four other kinds of HSCs using the same procedures. Moreover, the 
Kl peptide detected was a little unusual with respect to solubihty versus urea concentration. Epidermal Kl peptide is usually solubilized by 6-8 
M urea and reductant; however, the Kl peptide in cultured HSCs was about 80-90% extracted by l-2 M urea in a stepwise extraction procedure. 
This finding may have important implications regarding evaluation of keratin extracted from normal epidermal and cultured keratinocytes. 
Kl keratin peptide; Cultured squamous cell carcinoma 
1. INTRODUCTION 
Keratins, epithelial intermediate filament proteins, 
are especially abundant in stratified squamous epithelial 
tissues, where they comprise the major differentiation- 
specific products of these cells. In epithelial tissues, ker- 
atins are differentially expressed as specific pairs of type 
I and type II proteins, both of which are essential for 
filament formation [l-3]. Thus, for example, K5 (type 
II) and K14 (type I) are co-expressed in basal cells. As 
basal cells differentiate and move into suprabasal lay- 
ers, the above two keratin peptides are down-regulated, 
and Kl (type II) and KIO (type I) peptides are expressed 
more in the suprabasal cells of the epidermis. Each ker- 
atin is encoded by its own gene and is expressed in 
keratin pairs containing one acidic (type I) and one 
basic (type II) protein according to specific rules 14-71. 
Kl/KlO is a characteristic keratin pair of suprabasal 
keratinocytes and may be essential in constructing and 
maintaining structural and functional requirements 
during terminal differentiation 181. 
Hereditary epidermolysis bullosa simplex (EBS), a 
bullous skin disease, is reportedly based on an abnor- 
mal and distinctive organization of cytokeratins 19). The 
N- and C-terminal rod domains of epidermal keratin 
have also been shown to be essential to normal keratin 
filament formation [lO,l 11. When the C-terminal dele- 
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tion mutant K14 keratin gene was used in transient 
t~~nsfe~tion i  vitro and transgenic mice in vivo, keratin 
filament formation was markedly altered, with keratin 
aggregates in basal cells [12], and the mice exhibited 
abnormalities in their epidermal architecture [13] resem- 
bling a group of genetic disorders known as EBS, i.e. 
all Dowling-Meara EBS point mutations indicated were 
in the rod domain of either the K5 [14] or K14 [15] 
protein. In addition, a similar point mutation was rec- 
ognized in the central portion of K14 in Koebner EBS 
[16]. They were actually found to be the genetic cause 
of the disease [ 151. Obviously normal keratin peptide is 
required to form the keratin filament in the basal cells 
of the epidermis, based on the many recent findings 
about EBS above. 
Although K5, K6, K14, K16, and K17 keratins have 
been found in cultured human squamous cell carcino- 
mas (SCC) [17], Kl [lS] had never been detected [17,19-- 
211. Thus, it was previously believed that cultured SCC 
cells characteristically had no keratins larger than 60 
kDa. Quite recently, this Kl peptide, though not abun- 
dant, was determined to be present in two cultured 
HSCs when a different buffer was employed in prepar- 
ing the cells 1221. 
In this paper, we report the widespread presence of 
Kl peptide in cultured HSCs. 
2. MATERIALS AND METHODS 
Dulbecco’s medium (DMEM) and fetal calf serum (FCS) were pur- 
chased from Dainihon Co., OSaka, Japan. [a-32P]dCTP (3000 Gil 
mmol) and [y-3’P]ATP (3000 Ciimmol) were purchased from Amer- 
sham Co. and used for labeling the cDNA probes. 
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2. I. Cell cultures 
The established cell lines HSCs-2, -4 and A-431 (Cell-No. JCRB 
0622, 0624 and 9009, respectively; The Japanese Cancer Research 
Resources Bank. Tokyo, Japan) and HSC-1 [23] were derived from 
well-differentiated SCCs of the mouth, tongue, vulva and epidermis, 
respectively. These cells were seriahy cultured at plating densities of 
about 1.5 x 10’ cells/cm’ in DMEM supplemented with 10% FCS, 
penicillin (100 units/ml), streptomycin (50 fig/ml), kanamycin (50 @gl 
ml) and hydrocortisone (0.4,@ml) at 37°C in a gas phase which was 
95% air and 5% CO?. 
2.2. E.*traction of’keratin polypeptides 
After four days, 4 plates of cultured cells were quickly rinsed twice 
with PBS and scraped with a rubber policeman using 1 ml of 10 mM 
Tris-HCI (pH 7.4)/10 mM EDTA/phe~~yimetl~yisulfonyl fluoride 
(PMSF; 0.3 mgiml) (Buffer A). The cells obtained were divided into 
two fractions. One fraction was washed, sonicated (15 s x 3 times) and 
centrifuged (10,000 x g, 10 min) with 1 ml of Buffer A. The other 
fraction was treated in a similar manner with I .5 M KC1/0.5% Triton 
X-100/140 mM NaClilO mM Tris-HC1 (pH 7.4)/l mM EDTAlPMSF 
(0.1 mg/ml) (Buffer B). After repeating the above procedure 3 times. 
both the resulting final residues were treated with 50 ~1 of 10 M 
urea/5% 2-ME at 37°C for 6 h [24]. 
2.3. One- and two-dimensional pof~ucrylamide gel eirctrophor-csis 
(PAGE) 
SDS-PAGE was performed according to the method described by 
Laemmli (251. Analysis of keratin peptides by two-dimensional PAGE 
was performed as described by O’FarreI [26] using pH 35 10 am- 
pholines (LKB, Bromma, Sweden). 
2.4. Immunoblot analyses 
After electrophoresis, the unstained gels were transferred electri- 
cally to nitrocellulose membranes at 100 mA for 16 h, and the mem- 
branes were reacted with keratin mon~ional antibody (34bB4 [27- 
291; ENZO Diagnostics, NY. USA, RKSE60 [30.31], SANBIO B.V., 
The Netherlands, reacting with Kl and KlO peptides, respectively) 
using an indirect immunologic technique [32]. 
2.5. Northern blot ana1y.G.~ 
The Kl probe [21] was prepared at the S’end with T4 polynucleotide 
kinase and [y-3ZP]ATP. A labeled K10 probe was prepared according 
to the method described in a random primer preparation kit (Takara 
Shuzou Co., Osaka, Japan) using [d-“P]dCTP and Klenow fragment. 
Total RNA was prepared from HSCs-1, -2, -4 and A-431 cells by the 
guanidine isothiocyanate procedure [33]. Poly(A)‘RNA, isolated on 
an oligo(dT) cellulose column [34], was subjected to electrophoresis on 
1% agarose/fo~aldehyde gel and transferred to a nitro~ellulose mem- 
brane [35]. The RNA blot was hybridized with the above “P-labeled 
probes prepared from the 5’ end by the T4 polynucleotide kinase 
reaction and random primer preparation method. respectively. 
2.6 Urea stepwise-extraction qf keratin peptides 
After washing the residue with Buffer A. the residue obtained was 
treated with 50 ~1 of I M urea/5% 2-ME for 3 h at 37°C. Then the 
supernatant was removed by centrifugation at 10,000 x g, for 10 min 
at 4°C. The resulting residue was further treated with 50 ~1 of 2 M 
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Fig. 1. SDS-PAGE of the keratin peptides extracted from cultured 
human HSCs-1, -2, -4, and A-431. 0.1% Coomassie brilliant blue 
(CBB) R-250 staining after electrophoresis of the extracts. (1) Stand- 
ard proteins, 92.5: phosphorylase A, 68: bovine serum albumin, 45; 
ovalbumin, 25; chymotrypsinogen A. (2) Extracts of HSC-1 treated 
with Buffer A. (3) Extracts of HSC-1 treated with Buffer 8. (4) Ex- 
tracts of HSC-2 treated with Buffer A. (5) Extracts of HSC-2 treated 
with Buffer B. (6) Extracts of HSC4 treated with Buffer A. (7) Ex- 
tracts of HSC-4 treated with Buffer B. (8) Extracts of A-431 treated 
with Buffer A, (9) Extracts of A-431 treated with Buffer B. Numbers 
on left indicate positions of molecular mass standards (kDa).* = 68 
kDa keratin peptide. 
urea/j% 2-ME under the same conditions and subsequently extracted 
with 50~1 of 6 M urea/S% 2-ME for 3 h at 37°C. Each extract obtained 
in three steps was treated with 2 x SDS sample solution [25] at 100°C 
for 3 min and then subjected to SDS-PAGE containing 10% acryl- 
amide. The Kl kerdtins extracted at the three urea concentrations 
were estimated by LHB 222, Ultro Scan XL, enhanced laser densito- 
metry (LKB, Bromma, Sweden). 
3. RESULTS AND DISCUSSION 
Up until now many investigators have used high salt/ 
Triton X- 100 (Buffer B) as the washing buffer to extract 
keratin peptides from cultured SCC cells. The above 
solution was used originally to remove fatty substances 
and the many hydrophilic substances contained in the 
experimental materials (tumors or living tissues). 
Hence, this specific solution can also be used to extract 
keratin from cultured cells. However, there is generally 
less extractable material in cultured cells than in living 
tissue or tumors. Thus, to treat cultured cells with such 
Fig. 2. ZD-PAGE of keratin peptides extracted from cultured human HSCs-I, -2, -4, and A-431 (CBB staining). (A) Extracts of cultured HSC-I 
treated with Buffer A. (B) Extracts of cultured HSC-1 treated with Buffer B. (C) Extracts of cultured HSC-2 treated with Buffer A. (D) Extracts 
of cultured HSC-2 treated with Buffer B. (E) Extracts of cultured HSC-4 treated with Buffer A. (F) Extracts of cultured HSC-4 treated with 
Buffer B. (G) Extracts of cultured A-431 treated with Buffer A. (H) Extracts of cultured A-43 1 treated with Buffer B. Standard proteins were used: 
p = 3’-phosphoglycerokinase (PI 7.4, M, 43 kDa; b = bovine serum albumin (PI 6.35. M, 68 kDa); a = rabbit a-actin (PI 5.4, M, 42 kDa). The 
numbers denoted keratin nomenclature according to the Mall catalogue [l]. The first-dimensional separation was done by non-equilibrium pH 
gradient gel electrophoresis (NEpGE), and the second-dinlensional separation by SDS-PAGE. 
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Fig. 3. Immunoblot analyses with keratin monoclonal antibodies. (A) Immunoblot analyses with 34/3B4 against Kl keratin peptide. (B) Immunoblot 
analyses with RKSE60 against KlO keratin peptide. Lane 1 = standard proteins which stained with 0.04% CBB R-250 after transfer. Lanes 2-9 
designated in Fig. 1 and each strip transferred from Fig. 1 samples, respectively. Lanes 10 and 11 were transferred from extracts of normal epidermis 
with Buffers A and B, respectively, as positive controls. * = 68 kDa keratin (Kl) peptide; 4 = 56.5 kDa keratin (KlO) peptide. 
a strong solution to extract keratin may remove certain 
unstable keratins along with affinity substances with the 
buffer. The keratin patterns of HSCs-1, -2, -4, and A- 
43 1 using Buffer B are shown (Fig. 1, lanes 3, 5, 7 and 
9, respectively). The major bands from cultured HSCs- 
1, -2, and A-431 were 58 kDa, 56.5 kDa, 52.5 kDa, 50 
kDa, 45 kDa and 40 kDa (corresponding to KS, KlO, 
KS, K14, K18 and K19, respectively) [l]. On the other 
hand, keratin peptides from HSC-4 consisted of K5, 
K8, K18, and K19. These findings were in excellent 
agreement with those in many earlier reports [17-201, 
and this tendency in keratin expression patterns may 
have two types in human cultured HSCs, combined with 
results of previous paper [22]. Moreover, no large kera- 
tin peptides (60---68 kDa) were present in these cultured 
cells described thus far. When Buffer A, a low-salt aque- 
ous solution, was used as the washing buffer, surpris- 
ingly a 68 kDa band was detected, though not intense, 
in the extracts from HSCs-1, -2, -4, and A-431 (Fig. 1. 
lanes 2, 4, 6 en 8). Moreover, these results were highly 
reproducible when the experiments were repeated sev- 
eral times. To further verify the keratins extracted by 
two different buffers, we analyzed these extracts by 2D- 
PAGE, because 2D-PAGE systems are superior in iden- 
tifying keratin peptides with similar mobilities and isoe- 
lectric points. As we expected to some extent from the 
results in Fig. 1, Kl peptide was present, though not 
intense, and appropriately detected only when Buffer A 
was used (Fig. 2A, C, E, and G). On the other hand, this 
peptide was not present when treated with Buffer B 
(Fig. 2B, D, F, and H). Though very little Kl peptide 
8 
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Fig.4. Northern blot hybridization of HSC mRNAs. Poly(A)’ RNAs 
(2 pg each) prepared from human cultured HSCs-1, -2, -4 and A-431 
total RNA were electrophoresed on 1% agarose/O.66 M fo~aldehyde 
gel, then blotted onto a nitrocellulose membrane. 1 = HSC-I; 2 = 
HSC-2: 3 = HSC4; 4 = A-431; 5 = normal epidermis as a positive 
control. The membrane was hybridized with a jZP-labeled Kl and KlO 
probes as described in Materials and Methods. Ribosomal 28 S (4.7 
kb) and 18 S (1.9 kb) RNAs were used as size markers. RNA blots 
(A) and (B) were analyzed with Kl and KlO probes, respectively. 
* = Kl mRNA (2.5 kb); 4 = KIO mRNA (2.3 kb). 
is involved, these findings suggest its presence in the 
above HSCs. 
To immunologically verify whether the 68 kDa band 
was Kl peptide 1211, we transferred it from the un- 
stained gel to nitrocellulose membranes after electro- 
phoresis and reacted it with the monoclonal antibody 
34PB4 [27-291. The 68 kDa band was detected in ex- 
tracts and control fractions treated with Buffer A (Fig. 
3A, lanes 24, 6, and 8). Moreover, the same band was 
also observed faintly in extracts treated with Buffer B 
after treatment with the same antibody (Fig. 3A, lanes 
3, 5, 7, and 9). These data suggest that Kl peptide may 
be removed by Buffer B or remain in only very small 
amounts, and so many investigators may have over- 
looked its presence in cultured SCC when staining with 
CBB alone so far. In addition, KlO peptide, a pair 
keratin of Kl peptide, also investigated using keratin 
monoclonal antibody RKSE60. As shown in Fig. 3B, 
no detection of it was present in these cultured cells, 
except normal epidermis (Fig. 3B, lanes 10 and 11). 
As reported to involve Kl mRNA in HSCs-3 and -5 
in our previous paper [22], to investigate whether the 
mRNA of Kl was present in HSCs-1, -2, -4, and A-43 1 
cells, we analyzed their mRNAs by Northern blots 
using a radiolabeled probe specific for Kl peptide. The 
specific Kl probe hybridized to a single RNA band of 
about 2.5 kilobases (kb), which was consistent with the 
size of Kl mRNA [21], as shown in Fig. 4A. However, 
the mRNA content of the various HSC cells was not 
constant, even though equal amounts of poly(A)’ RNA 
were employed in the experiments. This may be related 
to the degree of cell differentiation and Kl peptide ex- 
pression in individual cells. 
In general, Kl/KlO forms keratin filaments and are 
expressed especially in the suprabasal keratinocytes of 
the epidermis [4-Q however, Kl/KlO expression was 
less than that of other keratin peptides in HSCs-1, -2, 
-4 and A-43 1 (Figs. 1 and 2). These findings may be due 
to exposure of the cultured cells to the strong buffer, or 
may be due to the development of epidermal tumors 
rather than normal epidermis. Though not in large 
amounts, Kl peptide was present in HSCs-1 to -5 or 
A-431 and, we also attempted to determine whether 
KlO peptide formed keratin filameI~ts with Kl in HSCs. 
Immunological reactions using RKSE60 keratin mono- 
clonal antibody and preparation of KlO mRNAs were 
performed using the same methods described above. 
The results are shown in Figs. 3B and 4B and no KIO 
peptide was found in HSCs-1 to -5 or A-431. Thus, Kl 
peptide may not form keratin filaments with KlO pep- 
tide, or if Kl peptide is formed with other type I keratin 
peptides. the filaments formed may be unstable and 
incomplete. As it is said that type II keratin induces type 
I keratin 1361, the Kl peptide itself may be unstable or 
be a point mutation in the case of epidermolytic hyperk- 
eratosis as reported quite recently [37-391. Hence, we 
investigated whether Kl peptide in HSCs retains its 
original solubility properties in urea. As described in 
Materials and Methods, each extract obained by urea 
stepwise-extraction was subjected to SDS-PAGE. As 
shown in Fig. 5, intact epidermal Kl peptide is ex- 
tracted by 6-8 M urea/2-ME [40]; about 80-90% of this 
Kl peptide was extracted in the l-2 M urea/reductant 
fraction according to the data in Fig. 5. Since the so- 
called Kl peptide was extracted from the epidermis with 
6 M reductant, as shown in Fig. 5, we may reasonably 
conclude that the Kl peptide extracted had changed 
considerably. Finally, we performed the above experi- 
ments 3-4 times each and obtained the very reproduci- 
ble results described in this paper. Based on our findings 
in this study, the following appears to be true. (1) While 
Kl was not expressed abundantly, its presence was con- 
9 
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Fig. 5. SDS-gel electrophoresis water-insoluble HSC keratin peptides sequentially extracted with increasing concentrations of urea, stained with 
CBB R-250. About 1% (v/v) of proteins sequentiaiIy extracted with IO mM Tris-HCI (pH 7.4)15% Z-ME, containing I M urea (A), 2 M urea (B) 
and 6 M urea(C) were analyzed on 10% a~rylamid~ gels. 1 = standard proteins; 2 = HSC-I; 3 = HSC-2; 4 = HSC-4; 5 = A-431; 6 = normal epidermis. 
(D) Quantitative analyses of KI peptide extracted from four WCs and nomlal epidermis by sequential urea con~ntr~tions. 
IO 
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firmed in HSCs extracts treated with Buffer A. Based 
on these findings and the results of the previous study 
[22], Kl keratin peptide may be widely present in HSCs. 
(2) KlO peptide was not found in HSCs, i.e. Kl may 
form keratin filaments with other type I keratins, but 
not KIO peptide. (3) The Kl peptide may be altered with 
respect to its urea solubility and become unstable or 
developed affinity when exposed to Buffer B. Many 
investigators may therefore have overlooked Kl . It was 
discovered after the chance use of an aqueous buffer 
solution. 
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